When are NOACs (dabigatran/Pradaxa, rivaroxaban/Xarelto, apixaban/Eliquis, edoxaban) preferred over warfarin therapy for anticoagulation in tx of afib or aflutter. a) In patients with non-valvular atrial fibrillation without a history of heart valve replacement
b) When there is a preference for a fixed-dose regimen without the need for frequent monitoring
c) When there is a need to avoid potential drug and food interactions associated with warfarin
d) In patients at high risk for falls or intracranial bleeding